Oncotarget

Research Papers:

Widespread folate receptor expression in pediatric and adolescent solid tumors - opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine

Ashley C. Dodd, Nitin R. Wadhwani, Alison Lehane, Rom Brown, Kyle L. MacQuarrie, Seth D. Goldstein and Timothy B. Lautz _

PDF  |  Full Text  |  How to cite

Oncotarget. 2025; 16:759-767. https://doi.org/10.18632/oncotarget.28772

Metrics: PDF 55 views  |   Full Text 414 views  |   ?  


Abstract

Ashley C. Dodd1, Nitin R. Wadhwani2, Alison Lehane1, Rom Brown1, Kyle L. MacQuarrie3,4, Seth D. Goldstein1,5 and Timothy B. Lautz1,5

1 Department of Surgery, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA

2 Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA

3 Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA

4 Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA

5 Division of Pediatric Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Correspondence to:

Timothy B. Lautz, email: [email protected]

Keywords: folate receptor; fluorescent-guided surgery; pediatric tumors; pafolacianine; RNA sequencing

Received: July 15, 2025     Accepted: October 03, 2025     Published: October 16, 2025

Copyright: © 2025 Dodd et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Contemporary fluorescence-guided surgery has evolved principally based on the uses and limitations of the contrast agent indocyanine green (ICG). A second generation of novel fluorescent agents are under development to target specific molecular markers on tumor cells and/or the tumor micro-environment. Pafolacianine, a molecular agent targeting the folate receptor (FR), is the first of these approved for use in adults, but its potential utility in pediatric cancers is unknown. In this study, we performed immunohistochemistry staining on slides obtained from a range of pediatric patients with solid tumors. Slides were stained with antibodies to FRα and FRβ, and fluorescence was quantified. Separately, publicly available RNA sequencing data were queried for both FRα and FRβ expression in various pediatric tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28772